The 18th Annual Non-Dilutive Funding Summit

The 18th Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with directors at ARPA-H, BARDA, SEED, NIA, NHLBI, NIAID, NINDS, and CIRM, so the innovators could learn about non-dilutive funding opportunities for their R&D directly from the funding agencies.

This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences. The 19th Non-Dilutive Funding Summit will be January 10, 2024.

Translational Research – NINDS Programs

The National Institute of Neurological Disorders and Stroke (NINDS)

The National Institute of Neurological Disorders and Stroke (NINDS) seeks fundamental knowledge about the brain and nervous system and uses that knowledge to reduce the burden of neurological disease for all people. To that end, NINDS supports basic, translational, and clinical neuroscience research through grants-in-aid, contracts, scientific meetings, as well as through research in its own laboratories and clinics, and funds and conducts training and career development programs to increase basic, translational and clinical neuroscience expertise and ensure a vibrant, talented, and diverse work force.

Dr. Charles L. Cywin

Dr. Charles L. Cywin is the Director of Small Molecule Neurotherapeutic Development in the Division of Translational Research at the Nation Insititute of Neurological Disorders & Stroke (NINDS) of the NIH.

For six years, Dr. Cywin has also served as the Program Director for the Blueprint Neurotherapeutics Network (BPN), a trans-NIH network of grantees, contract research organizations, and expert consultants which provides non-dilutive funding to advance promising small molecule drug discovery projects in neuroscience.

He has also served as the Contract Officer Representative for several large NIH R&D contracts and spearheaded the HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain, leading and coordinating the portfolio of neuroscience and pain drug discovery projects ranging from early discovery to Phase I trials.

Prior to joining NIH, Dr. Cywin spent 17 years at Boehringer Ingelheim Pharmaceuticals where he was Director of Medicinal Chemistry and was responsible for Hit to Lead and Lead Optimization programs focused on successful clinical candidate selection in several therapeutic areas. He created the lead discovery team, the parallel synthesis group, and led the efforts to identify and implement new technologies, infrastructure and outsourcing in medicinal chemistry.

Dr. Cywin received his Bachelor’s degree in chemistry from Providence College. He performed his doctoral training at Syracuse University where he was a University Fellow and focused on natural product synthesis. He completed his postdoctoral fellowship with Professor E. J. Corey at Harvard focusing on asymmetric catalysis.

Reserve Your Place Today

Register Now Free of Charge
For the 19th Annual Non-Dilutive Funding Summit (NDFS)
Wednesday, January 10, 2024
To Join Hundreds of Life Science Industry Leaders
In Learning about Non-Dilutive Funding Opportunities for Your R&D.

Speakers, location, and all other details to be announced.
Register now to receive updates.

Follow us on LinkedIn or request our newsletter to receive:

  • News about non-dilutive funding opportunities
  • Announcements about conferences with the best partnering for life science professionals
  • Discounts for those conferences.